Bristol Settlement Over Vanlev Could Require Clinical Trial Disclosure
This article was originally published in The Pink Sheet Daily
Executive Summary
Proposed settlement would resolve class action suit alleging Bristol misled investors about safety problems with its failed investigational antihypertensive.